Muna Bhanji - Apr 28, 2022 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
Director
Signature
/s/ James Basta, Attorney-in-Fact
Stock symbol
NTLA
Transactions as of
Apr 28, 2022
Transactions value $
$0
Form type
4
Date filed
5/2/2022, 09:49 PM
Previous filing
Apr 1, 2022
Next filing
May 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Award $0 +7.95K $0.00 7.95K Apr 28, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NTLA Stock Option (Right to Buy) Award $0 +11.7K $0.00 11.7K Apr 28, 2022 Common Stock 11.7K $50.29 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2 This option was granted on April 28, 2022 with respect to 11,700 shares of Common Stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan, with 33 1/3 % vesting on April 28, 2023 and the remaining 66 2/3% vesting in 8 substantially equal quarterly installments thereafter.